search button
Open Access

Detection of serum HE4 levels contributes to the diagnosis of lung cancer

  • Authors:
    • Jun Li
    • Yuzhu Li
    • Lijing Huo
    • Ruyi Sun
    • Xiao Liu
    • Quan Gu
    • Anping Li
    • Sugui Han
    • Hongmei Liu
    • Yufeng Li
    • Yumin Zhang

  • View Affiliations

  • Published online on: April 27, 2023     https://doi.org/10.3892/ol.2023.13841
  • Article Number: 255

  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lung cancer (LC) is the most frequently diagnosed cancer and is the leading cause of cancer‑associated death. Serum markers that exhibit high sensitivity and specificity for LC may assist in the diagnosis and prognosis of LC. The banked serum samples from 599 individuals, including 201 healthy controls, 124 patients with benign lung diseases, and 274 LC cases, were used. The serum concentrations of biomarkers were determined by electrochemiluminescence immunoassay and chemiluminescence immunoassay. The results showed that the serum human epididymis secretory protein 4 (HE4) levels in the LC group were significantly higher than in the healthy and benign lung disease groups. The serum levels of HE4, NSE, and CYFRA21‑1 were significantly higher in patients with LC compared to those in the benign lung disease group. The area under the area under the curve (AUC) of HE4 for discriminating LC from healthy controls was 0.851 (95% CI, 0.818‑0.884) and 0.739 (95% CI, 0.695‑0.783), 0.747 (95% CI, 0.704‑0.790), 0.626 (95% CI, 0.577‑0.676), and 0.700 (95% CI, 0.653‑0.747) for NSE, CYFRA21‑1, SCC, and ProGRP, respectively. The AUC value of the combination of serum HE4 combined with NSE, CYFRA21‑1, SCC, and proGRP for cancer diagnosis was 0.896 (95% CI, 0.868‑0.923). In early LC, the AUC value of HE4 for discriminating early LC from healthy controls was 0.802 (95% CI, 0.758‑0.845), 0.728 (95% CI, 0.679‑0.778), 0.699 (95% CI, 0.646‑0.752), 0.605 (95% CI, 0.548‑0.662), and 0.685 (95% CI, 0.630‑0.739) for NSE, CYFRA21‑1, SCC, and ProGRP, respectively. The AUC value of the combination of serum HE4 with NSE, CYFRA21‑1, SCC, and proGRP for early LC was 0.867 (95% CI, 0.831‑0.903). Serum HE4 is a promising LC biomarker, particularly for early‑stage LC. Measuring serum HE4 levels may improve the diagnostic efficiency of LC.
View Figures
View References

Related Articles

Journal Cover

June-2023
Volume 25 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li J, Li Y, Huo L, Sun R, Liu X, Gu Q, Li A, Han S, Liu H, Li Y, Li Y, et al: Detection of serum HE4 levels contributes to the diagnosis of lung cancer. Oncol Lett 25: 255, 2023
APA
Li, J., Li, Y., Huo, L., Sun, R., Liu, X., Gu, Q. ... Zhang, Y. (2023). Detection of serum HE4 levels contributes to the diagnosis of lung cancer. Oncology Letters, 25, 255. https://doi.org/10.3892/ol.2023.13841
MLA
Li, J., Li, Y., Huo, L., Sun, R., Liu, X., Gu, Q., Li, A., Han, S., Liu, H., Li, Y., Zhang, Y."Detection of serum HE4 levels contributes to the diagnosis of lung cancer". Oncology Letters 25.6 (2023): 255.
Chicago
Li, J., Li, Y., Huo, L., Sun, R., Liu, X., Gu, Q., Li, A., Han, S., Liu, H., Li, Y., Zhang, Y."Detection of serum HE4 levels contributes to the diagnosis of lung cancer". Oncology Letters 25, no. 6 (2023): 255. https://doi.org/10.3892/ol.2023.13841